Correction to: Pediatric Nephrology https://doi.org/10.1007/s00467-018-4054-8
The original version of this article unfortunately contained three mistakes. In Table 1 , the last line under BKey Inclusion Criteria^should read BNormal or clinically acceptable ECGs at screening and at day -1.^In addition, the abbreviation BIPî n the legend to Table 1 stands for Binvestigational product.T o Figure 1 , BAE follow up^was supposed to be on BDay 7.T he corrected versions of Table 1 and Figure 1 are given below.
The online version of the original article can be found at https://doi.org/ 10.1007/s00467-018-4054-8 Fig. 1 Study design and treatment schema. Screening was conducted between days − 21 to − 2. Subjects entered the clinical unit on day -1 to undergo safety laboratory testing and baseline PD sampling and remained in residency until 24-h post-dose procedures were completed. Following pre-dose procedures and dosing on day 1, subjects underwent a 72-h period of PK, PD sampling, and safety monitoring. End of study procedures were conducted on day 4 (72 h post-dose). SAE follow-up was conducted to day 30. PD pharmacodynamic, PK pharmacokinetic. AE adverse evemt. SAE serious adverse event
